Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Paul Angulo, David E. Kleiner, Sanne Dam‐Larsen et al. · Gastroenterology · 2015 · 3K citations · Full text

Medicine, Internal Medicine, Pathology +12

Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways

Hidenori Ichijo, Eisuke Nishida, Kenji Irie et al. · Science · 1997 · 2.3K citations

Life Sciences, Cell Biology, Molecular Biology +16

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Mattias Ekstedt, Hannes Hagström, Patrik Nasr et al. · Hepatology · 2014 · 2.3K citations · Full text

Medicine, Internal Medicine, Pathology +17

NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

Mazen Noureddin, Aarshi Vipani, Catherine Bresee et al. · The American Journal of Gastroenterology · 2018 · 575 citations · Full text

Medicine, Internal Medicine, Surgery +16

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Rohit Loomba, Eric Lawitz, Parvez Mantry et al. · Hepatology · 2017 · 553 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16